Si Ying Tan, Veronique Tan, Wei Sean Yong, Preetha Madhukumar, Benita Kiat Tee Tan, Julie Liana Binte Hamzah, Sue Zann Lim, Clarissa Tay

Review of ductal carcinoma in-situ and invasive carcinoma in breast fibroepithelial lesions

Abstract Disclosures
Abstract:
Breast fibroepithelial lesions (FEL) are common amongst women. Amongst FEL, the incidence of DCIS/carcinoma in breast is rare. There are currently no guidelines to advice closer monitoring for FEL with certain red flags or high-risk patient profiles and decision for longer follow-up or surgery is based on clinician acumen. The current largest study of carcinoma in FEL is a study of 62 patients but with no recommendations on follow up and treatment. Another more recent study published in 2014 of 30 patients in Taiwan which mainly discuss the optimal treatment of breast cancer in fibroadenoma. The mean duration from finding a FA to surgical excision was 61.2 months which is significantly longer than the follow up period of 2 years in our local context for stable FEL. There is also a lack of consensus regarding RT for carcinoma in FEL after breast conserving surgery (BCS) with some arguing that FEL are well defined with a capsule and this if initial margins are negative, BCS without RT may suffice. It is unsure if adjuvant treatment would still follow the general principles of therapy for the in-situ or infiltrative breast cancers for carcinoma within a well-defined capsulated FEL.

This study aims to identify risk factors of carcinoma in fibroepithelial lesion and to suggest appropriate follow up duration with respect to low vs high risk profiles based on patient demographic and imaging findings. Our secondary outcome will aim to review treatment with respect to type of surgery and adjuvant therapies, or the absence of it, and its effectiveness measured via overall survival (OS) and, disease-free survival (DFS).

Due to rare incidence of carcinoma in FEL, the study sample is expected to be small. We aim to retrospectively review the data from the JBCR database of all eligible patients from year 2000-2022.

Joint Breast Cancer Registry Singapore